Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PYD001
MIFTS: 57

Pyoderma Gangrenosum

Categories: Bone diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pyoderma Gangrenosum

About this section

MalaCards integrated aliases for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 12 76 53 59 55 44 15 73

Characteristics:

Orphanet epidemiological data:

59
pyoderma gangrenosum
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare systemic and rhumatological diseases
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8553
ICD10 33 L88
ICD9CM 35 686.01
MeSH 44 D017511
SNOMED-CT 68 74578003
Orphanet 59 ORPHA48104
MESH via Orphanet 45 D017511
UMLS via Orphanet 74 C0085652
ICD10 via Orphanet 34 L88
UMLS 73 C0085652
Sources

Summaries for Pyoderma Gangrenosum

About this section
NIH Rare Diseases : 53 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, Crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. Treatment involves wound care and the use of anti-inflammatory agents, including antibiotics, corticosteroids, immunosuppressants, and biologics. 

MalaCards based summary : Pyoderma Gangrenosum is related to pyogenic arthritis, pyoderma gangrenosum and acne and ileocolitis. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Infliximab and Dermatologic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and t cells, and related phenotypes are fever and arthralgia

Wikipedia : 76 Pyoderma gangrenosum is a condition that causes tissue to become necrotic, causing deep ulcers that... more...

Sources

Related Diseases for Pyoderma Gangrenosum

About this section

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
# Related Disease Score Top Affiliating Genes
1 pyogenic arthritis, pyoderma gangrenosum and acne 34.6 IL1R1 PSTPIP1
2 ileocolitis 32.3 NOD2 TNF
3 pyoderma 31.8 CXCL8 IL1R1 ITGB2 MEFV MMP10 NOD2
4 colitis 31.3 CXCL8 NOD2 TNF
5 ulcerative colitis 31.2 CXCL8 NOD2 TNF
6 hidradenitis 31.2 NOD2 TNF
7 hidradenitis suppurativa 30.9 NOD2 TNF
8 arthritis 30.9 CXCL8 NOD2 PSTPIP1 TNF
9 fasciitis 30.8 CXCL8 TNF
10 inflammatory bowel disease 30.8 CXCL8 IL1R1 NOD2 TNF
11 sapho syndrome 30.5 CXCL8 NOD2
12 crohn's colitis 30.5 CXCL8 NOD2 TNF
13 rheumatoid arthritis 30.4 CXCL8 IL1R1 ITGB2 TNF
14 pouchitis 30.3 CXCL8 NOD2
15 cellulitis 30.2 IL1R1 TNF
16 erysipelas 30.1 MEFV TNF
17 spondylarthropathy 30.1 NOD2 TNF
18 ileitis 30.0 NOD2 TNF
19 uveitis 29.9 IL1R1 NOD2 TNF
20 acute respiratory distress syndrome 29.9 CXCL8 TNF
21 mooren's ulcer 29.8 ITGB2 NLRP3
22 behcet syndrome 29.7 CXCL8 MEFV NOD2 PSTPIP1 TNF
23 aphthous stomatitis 29.7 MEFV NLRP3 TNF
24 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 12.6
25 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 12.5
26 crohn's disease 11.7
27 polydactyly, postaxial, type a1 11.4
28 corticosteroid-sensitive aseptic abscesses 11.3
29 myelodysplastic syndrome 10.6
30 lymphoma 10.5
31 hepatitis 10.5
32 neurofibromatosis, type ii 10.4
33 breast reconstruction 10.4
34 vasculitis 10.4
35 leukemia 10.4
36 necrotizing fasciitis 10.4
37 subcorneal pustular dermatosis 10.3
38 psoriasis 10.3
39 systemic lupus erythematosus 10.3
40 granulomatosis with polyangiitis 10.3
41 osteomyelitis 10.3
42 sporotrichosis 10.3
43 lupus erythematosus 10.3
44 myeloma, multiple 10.3
45 autoimmune hepatitis 10.3
46 hepatitis c 10.3
47 leukocyte adhesion deficiency, type i 10.2
48 erythema elevatum diutinum 10.2
49 ectropion 10.2
50 agammaglobulinemia 10.2

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to Pyoderma Gangrenosum
Sources

Symptoms & Phenotypes for Pyoderma Gangrenosum

About this section

Human phenotypes related to Pyoderma Gangrenosum:

59 32 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
2 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
3 myelodysplasia 59 32 frequent (33%) Frequent (79-30%) HP:0002863
4 abnormal blistering of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0008066
5 inflammation of the large intestine 59 32 frequent (33%) Frequent (79-30%) HP:0002037
6 skin ulcer 59 32 hallmark (90%) Very frequent (99-80%) HP:0200042
7 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
8 papule 59 32 hallmark (90%) Very frequent (99-80%) HP:0200034
9 myositis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100614
10 skin vesicle 59 32 occasional (7.5%) Occasional (29-5%) HP:0200037
11 increased antibody level in blood 59 32 frequent (33%) Frequent (79-30%) HP:0010702
12 rheumatoid arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001370
13 pustule 59 32 frequent (33%) Frequent (79-30%) HP:0200039
14 atrophic scars 59 32 frequent (33%) Frequent (79-30%) HP:0001075
15 myeloid leukemia 59 32 frequent (33%) Frequent (79-30%) HP:0012324

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 IL1R1 ITGB2 MEFV NLRP3 NOD2 PSTPIP1
2 immune system MP:0005387 9.56 IL1R1 ITGB2 MEFV MMP10 NLRP3 NOD2
3 skeleton MP:0005390 9.1 IL1R1 ITGB2 MEFV NLRP3 NOD2 TNF
Sources

Drugs & Therapeutics for Pyoderma Gangrenosum

About this section

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Not Applicable 170277-31-3
2 Dermatologic Agents Phase 4,Phase 2,Not Applicable
3 Gastrointestinal Agents Phase 4,Not Applicable
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
5
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
6
Adalimumab Approved Phase 2, Phase 3,Phase 3 331731-18-1 16219006
7
Azathioprine Approved Phase 3 446-86-6 2265
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9 Anti-Bacterial Agents Phase 3
10 Anti-Infective Agents Phase 3
11 Mesalamine Phase 3,Phase 2 89-57-6
12 Analgesics, Non-Narcotic Phase 3
13 Peripheral Nervous System Agents Phase 3
14 Anti-Inflammatory Agents Phase 3,Phase 2
15 Analgesics Phase 3
16 Anti-Inflammatory Agents, Non-Steroidal Phase 3
17 Aspartic Acid Phase 3
18 alanine Phase 3
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Hormone Antagonists Phase 3
21 Liver Extracts Phase 3
22 N-Methylaspartate Phase 3
23 Immunosuppressive Agents Phase 3,Phase 2
24 Antimetabolites Phase 3
25 glucocorticoids Phase 3
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
27 Hormones Phase 3
28 Antimetabolites, Antineoplastic Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 Pharmaceutical Solutions Phase 3,Phase 2
31 Ixekizumab Approved, Investigational Phase 2 1143503-69-8
32
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
33 Antibodies, Monoclonal Phase 2,Phase 1
34 Immunoglobulins Phase 2,Phase 1
35 Antibodies Phase 2,Phase 1
36 Calcineurin Inhibitors Phase 2
37 Vedolizumab Approved 943609-66-3
38
Certolizumab pegol Approved 428863-50-7
39
Ustekinumab Approved, Investigational 815610-63-0

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
2 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
3 A Comparison of Once a Day Dose Compared to 2 Doses/Day Completed NCT00505778 Phase 3 Mesalamine Once-Daily;Mesalamine Twice-Daily
4 A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease Completed NCT00445432 Phase 2, Phase 3
5 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease Completed NCT01235689 Phase 3 Prednisone;Azathioprine
6 A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Recruiting NCT03311464 Phase 3 adalimumab
7 An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
8 An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
9 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
10 Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
11 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
12 Canakinumab for Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
13 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed NCT03137160 Phase 2
14 Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease Completed NCT01233570 Phase 2 Tacrolimus
15 Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis Completed NCT01036022 Phase 2 GSK1399686
16 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Recruiting NCT02733094 Phase 1, Phase 2 Secukinumab
17 Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Terminated NCT03072953 Phase 2 APD334
18 Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira;Humira
19 Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00690846 Phase 2 adalimumab
20 Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease Completed NCT00791557 Not Applicable Infliximab
21 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors Completed NCT00933296
22 Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases Recruiting NCT01952275
23 Entyvio (Vedolizumab) Long Term Safety Study Recruiting NCT02674308 Vedolizumab
24 Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease Recruiting NCT03495973 Ustekinumab
25 Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum Not yet recruiting NCT03636737
26 Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) Terminated NCT01577264

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pyoderma gangrenosum

Sources

Genetic Tests for Pyoderma Gangrenosum

About this section
Sources

Anatomical Context for Pyoderma Gangrenosum

About this section

MalaCards organs/tissues related to Pyoderma Gangrenosum:

41
Skin, Neutrophil, T Cells, Bone, Myeloid, Lung, B Cells
Sources

Publications for Pyoderma Gangrenosum

About this section

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 1165)
# Title Authors Year
1
Pyoderma gangrenosum: a review of pathogenesis and treatment. ( 29406827 )
2018
2
Pyoderma gangrenosum in the genital area: successful treatment using adalimumab. ( 29378677 )
2018
3
A case of chronic ulcer due to subcutaneous arteriolosclerosis in an obese patient mimicking pyoderma gangrenosum. ( 29887980 )
2018
4
Skin Grafting in Pyoderma Gangrenosum. ( 29896322 )
2018
5
The PARACELSUS score: A novel diagnostic tool for pyoderma gangrenosum. ( 29388188 )
2018
6
Pulmonary nodules and nodular scleritis in a teenager with superficial granulomatous pyoderma gangrenosum. ( 29243307 )
2018
7
A Case of Pyoderma Gangrenosum with Myelodysplastic Syndrome. ( 29853768 )
2018
8
Erythema elevatum diutinum associated with severe oropharyngeal ulceration and pyoderma gangrenosum. ( 29750453 )
2018
9
Endovenous Treatment of Varicose Veins in Patients With Pyoderma Gangrenosum. ( 29933301 )
2018
10
Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study. ( 29877043 )
2018
11
Pyoderma Gangrenosum of the Preauricular Area with Ulcerative Colitis: A Case Report and Review. ( 29890815 )
2018
12
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
13
A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe. ( 29854503 )
2018
14
A systematic review of pyoderma gangrenosum with pulmonmary involvement: clinical presentation, diagnosis, and management. ( 29377399 )
2018
15
Pyogenic arthritis pyoderma gangrenosum and acne syndrome: A rare but important diagnosis for antibiotic-resistant erysipelas-like erythema and osteonecrosis. ( 29943877 )
2018
16
Management of Facial Pyoderma Gangrenosum Using Platelet-Rich Fibrin: A Technical Report. ( 29425752 )
2018
17
Case of pyoderma gangrenosum-like sporotrichosis caused by Sporothrix globosa in a patient with ulcerative colitis. ( 29488248 )
2018
18
Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. ( 29450466 )
2018
19
Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. ( 29851121 )
2018
20
A case of neutrophilic dermatoses including pyoderma gangrenosum as a continuous disease spectrum to SAPHO syndrome. ( 29756300 )
2018
21
Pyoderma Gangrenosum of the Breast After Mastopexy. ( 29847306 )
2018
22
Cutaneous Diphtheria Mimicking Pyoderma Gangrenosum. ( 29282460 )
2018
23
Successful therapy of Pyoderma gangrenosum with a JAK2 inhibitor. ( 29451690 )
2018
24
Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma. ( 29362816 )
2018
25
A case of pyoderma gangrenosum, acne, hidradenitis suppurativa (PASH) syndrome associated with diabetes mellitus type 1 treated with adalimumab. ( 29368847 )
2018
26
Paraneoplastic Pyoderma Gangrenosum Associated with Rectal Adenocarcinoma. ( 29386837 )
2018
27
The rapidly evolving lesions of ulcerative pyoderma gangrenosum: a timeline. ( 29806128 )
2018
28
Recurrent pyoderma gangrenosum developed after a cesarean section with a 10-year interval. ( 29920658 )
2018
29
<i>LPIN2</i> gene mutation in a patient with overlapping neutrophilic disease (pyoderma gangrenosum and aseptic abscess syndrome). ( 29387759 )
2018
30
The Validity of the Diagnostic Code for Pyoderma Gangrenosum in an Electronic Database. ( 29451671 )
2018
31
Cocaine-induced pyoderma gangrenosum-like lesions. ( 29786948 )
2018
32
Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis. ( 29422812 )
2018
33
Central retinal arterial occlusion in a patient with pyoderma gangrenosum. ( 29941761 )
2018
34
Two cases of bullous pyoderma gangrenosum complicated by Epstein-Barr virus infection. ( 29952293 )
2018
35
Dental treatment of a rare case of pyoderma gangrenosum with aggressive periodontal disease. ( 29945713 )
2018
36
The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. ( 29438762 )
2018
37
Pyoderma Gangrenosum: A Review for the Gastroenterologist. ( 29788368 )
2018
38
Usefulness of metagenomic analysis in differential diagnosis for pyoderma gangrenosum. ( 29936877 )
2018
39
Pyoderma Gangrenosum Secondary to Severe Congenital Neutropenia. ( 29707446 )
2018
40
Pyoderma gangrenosum-like ulceration of the lower extremity secondary to sunitinib therapy: a case report. ( 29977559 )
2018
41
Imaging findings of sterile pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome: differential diagnosis and review of the literature. ( 30225645 )
2018
42
Bilateral pyoderma gangrenosum associated with ulcerative colitis and restorative proctocolectomy. ( 30470567 )
2018
43
Pyoderma Gangrenosum in Ulcerative Colitis. ( 30044941 )
2018
44
Pyoderma gangrenosum and primary cutaneous cryptococcosis in an ulcerative colitis patient. ( 29519678 )
2018
45
Atypical Behçet disease with endocarditis, pyoderma gangrenosum-like ulcers and methicillin-resistant Staphylococcus aureus-positive skin abscesses. ( 29984279 )
2018
46
Pyoderma gangrenosum and erythema elevatum diutinum associated with a high-risk myelodysplastic syndrome: case report. ( 30057994 )
2018
47
Diagnostic pitfalls in the differentiation between pyoderma gangrenosum and necrotizing fasciitis. ( 30457495 )
2018
48
A case of genital pyoderma gangrenosum successfully treated with cyclosporine without relapse of established follicular lymphoma. ( 29984287 )
2018
49
Pyoderma gangrenosum-like ulcerations in granulomatosis with polyangiitis: two cases and literature review. ( 29721696 )
2018
50
Tumor Necrosis Factor Antagonists in the Treatment of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Syndrome. ( 29989876 )
2018
Sources

Variations for Pyoderma Gangrenosum

About this section
Sources

Expression for Pyoderma Gangrenosum

About this section
Search GEO for disease gene expression data for Pyoderma Gangrenosum.
Sources

Pathways for Pyoderma Gangrenosum

About this section

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.69 CXCL8 IL1R1 ITGB2 MEFV NLRP3 NOD2
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.12 CXCL8 IL1R1 ITGB2 NOD2 TNF
3
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.59 CXCL8 MEFV NLRP3 NOD2 PSTPIP1 TNF
4
Human T-cell leukemia virus 1 infection 37
12.21 IL1R1 ITGB2 TNF
5
Toll Comparative Pathway 64
Show member pathways
 12.09 CXCL8 IL1R1 TNF
6
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 22
Show member pathways
 12.01 CXCL8 IL1R1 ITGB2 MMP10
7
Tuberculosis 37
12.01 ITGB2 NOD2 TNF
8
IL-1 Family Signaling Pathways 65
Show member pathways
 12 CXCL8 IL1R1 TNF
9
Bacterial infections in CF airways 22
Show member pathways
 11.95 CXCL8 IL1R1 TNF
10
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.81 ITGB2 MMP10 TNF
11
Spinal Cord Injury 1
11.78 CXCL8 IL1R1 TNF
12
Interleukin-4 and 13 signaling 66
11.74 CXCL8 ITGB2 TNF
13
NF-kappa B signaling pathway 37
11.63 CXCL8 IL1R1 TNF
14
Rheumatoid arthritis 37
11.59 CXCL8 ITGB2 TNF
15
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 66
Show member pathways
 11.52 MEFV NLRP3 NOD2 PSTPIP1
16
Legionellosis 37
11.35 CXCL8 ITGB2 TNF
17
Interleukin-10 signaling 66
11.27 CXCL8 IL1R1 TNF
18
Monoamine Transport 1
Show member pathways
 11.26 IL1R1 TNF
19
Amoebiasis 37
11.24 CXCL8 IL1R1 ITGB2 TNF
20
Malaria 37
11.23 CXCL8 ITGB2 TNF
21
Nucleotide-binding Oligomerization Domain (NOD) pathway 1
11.11 MEFV NLRP3 NOD2
22
IL1 and megakaryocytes in obesity 1
11 IL1R1 NLRP3
23
EBV LMP1 signaling 1
10.97 CXCL8 TNF
24
Canonical NF-kappaB pathway 1
10.93 NOD2 TNF
25
Overview of nanoparticle effects 1
10.83 CXCL8 TNF
26
Pertussis 37
10.81 CXCL8 ITGB2 NLRP3 TNF
Sources

GO Terms for Pyoderma Gangrenosum

About this section

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 8.92 IL1R1 ITGB2 NOD2 TNF

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 MEFV NLRP3 NOD2 PSTPIP1
2 innate immune response GO:0045087 9.86 MEFV NLRP3 NOD2 PSTPIP1
3 cytokine-mediated signaling pathway GO:0019221 9.81 CXCL8 IL1R1 ITGB2 TNF
4 negative regulation of inflammatory response GO:0050728 9.7 MEFV MVK NLRP3
5 cellular response to lipopolysaccharide GO:0071222 9.62 CXCL8 NLRP3 NOD2 TNF
6 positive regulation of nitric oxide biosynthetic process GO:0045429 9.6 ITGB2 TNF
7 receptor internalization GO:0031623 9.59 CXCL8 ITGB2
8 positive regulation of interleukin-1 beta secretion GO:0050718 9.58 NLRP3 NOD2
9 positive regulation of interleukin-8 production GO:0032757 9.57 NOD2 TNF
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.56 ITGB2 NLRP3 NOD2 TNF
11 microglial cell activation GO:0001774 9.55 ITGB2 TNF
12 embryonic digestive tract development GO:0048566 9.54 CXCL8 TNF
13 cellular response to peptidoglycan GO:0071224 9.49 NLRP3 NOD2
14 positive regulation of type 2 immune response GO:0002830 9.48 NLRP3 NOD2
15 cellular extravasation GO:0045123 9.46 ITGB2 TNF
16 defense response GO:0006952 9.46 CXCL8 NLRP3 NOD2 TNF
17 cytokine secretion involved in immune response GO:0002374 9.43 NLRP3 NOD2
18 detection of biotic stimulus GO:0009595 9.4 NLRP3 NOD2
19 positive regulation of prostaglandin-E synthase activity GO:2000363 9.37 ITGB2 NOD2
20 regulation of inflammatory response GO:0050727 9.26 IL1R1 NLRP3 NOD2 TNF
21 inflammatory response GO:0006954 9.17 CXCL8 IL1R1 ITGB2 MEFV NLRP3 PSTPIP1

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.35 MEFV MVK NLRP3 PSTPIP1 TNF
2 peptidoglycan binding GO:0042834 8.62 NLRP3 NOD2
Sources

Sources for Pyoderma Gangrenosum

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....